Skip to main content

The potential of oligonucleotide submicrob positively charged, emulsion ocular delivery system for age related macular degeneration

Objective

Navigable wants to investigate co-operation possibilities between two well-reputed research institutes and some European Sum’s to form a consortium for the research development and marketing of a remedy to treat ARMD. Age-related Macular Degeneration, a common eye disorder, the leading cause of severe vision loss in people older than 50 years. The wet form is the most severe type of macular degeneration notwithstanding it affects only 10% of those with the diseases it accounts for 90% of the blindness caused by ARMD.Today about 400,000 new cases of wet ARMD occur each year in the USA and Europe. Products existing today can treat only 15% of the patients with this form. Navigable wants, on basis of its oligonucleotide and Ribosome submicronpositively charged emulsion delivery system, to form the above alliance to bring the fruit of the cooperation as a remedy to the market which will result in dramatically increase of the treatment of wet ARMD and thus enormously reducing this cause of blindness.

Funding Scheme

EAW - Exploratory awards

Coordinator

NOVAGALI PHARMA SA
Address
Rue Pierre Fontaine 1
91000 Evry
France

Participants (1)

OPTIS BV
Netherlands
Address
Drenterstraat 20
1083 Amsterdam